Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 12/20 | 0.49 |
| ▸ | TTK | P33981 | 3/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 7/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502052 | 1.00 | PRKDC (0.49) | PRKDCTTKCSF1RATMKCNH2 | |
| SCHEMBL23948235 | 0.94 | PRKDC (0.47) | PRKDCTTKCSF1RATMKCNH2 | |
| SCHEMBL23948559 | 0.94 | PRKDC (0.47) | PRKDCTTKCSF1RATMKCNH2 | |
| SCHEMBL23625348 | 0.91 | PRKDC (0.54) | PRKDCTTKCSF1RMTORPIK3CA | |
| SCHEMBL20329835 | 0.88 | PRKDC (0.62) | PRKDCTTKCSF1RMTORPIK3CA | |
| SCHEMBL29352161 | 0.88 | PRKDC (0.62) | PRKDCTTKCSF1RMTORPIK3CA | |
| SCHEMBL23452636 | 0.88 | PRKDC (0.62) | PRKDCTTKCSF1RMTORPIK3CA | |
| SCHEMBL20299401 | 0.88 | PRKDC (0.62) | PRKDCTTKCSF1RMTORPIK3CA | |
| SCHEMBL23948573 | 0.86 | PRKDC (0.42) | PRKDCTTKCSF1RATMKCNH2 | |
| SCHEMBL28712893 | 0.86 | PRKDC (0.42) | PRKDCTTKCSF1RATMKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| CN-117940426-A | DNA-dependent protein kinase inhibitors, compositions and uses thereof | 英特利亚治疗股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4323360-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | Intellia Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022221696-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| WO-2021136462-A1 | FURAN DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| WO-2021136461-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | 成都百裕制药股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | CHEK1, DCK, CHEK2 | PRKDC 4/4885TTK 68/4885CSF1R 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.